Squarepoint Ops LLC Decreases Position in Altimmune, Inc. (NASDAQ:ALT)

Squarepoint Ops LLC lessened its holdings in Altimmune, Inc. (NASDAQ:ALTFree Report) by 76.2% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 14,706 shares of the company’s stock after selling 46,982 shares during the quarter. Squarepoint Ops LLC’s holdings in Altimmune were worth $106,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Wells Fargo & Company MN raised its stake in Altimmune by 69.3% during the 4th quarter. Wells Fargo & Company MN now owns 215,538 shares of the company’s stock worth $1,554,000 after acquiring an additional 88,209 shares in the last quarter. SBI Securities Co. Ltd. purchased a new stake in shares of Altimmune in the fourth quarter valued at about $45,000. Marshall Wace LLP acquired a new stake in shares of Altimmune in the fourth quarter valued at approximately $472,000. Bellevue Group AG lifted its stake in shares of Altimmune by 9.5% during the fourth quarter. Bellevue Group AG now owns 945,446 shares of the company’s stock valued at $6,817,000 after buying an additional 81,786 shares during the period. Finally, Bank of America Corp DE raised its holdings in Altimmune by 21.7% in the 4th quarter. Bank of America Corp DE now owns 181,889 shares of the company’s stock valued at $1,311,000 after acquiring an additional 32,382 shares during the last quarter. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Insider Buying and Selling at Altimmune

In related news, CFO Gregory L. Weaver purchased 10,000 shares of Altimmune stock in a transaction on Thursday, March 13th. The stock was bought at an average price of $5.20 per share, with a total value of $52,000.00. Following the completion of the transaction, the chief financial officer now directly owns 10,000 shares of the company’s stock, valued at approximately $52,000. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 4.10% of the company’s stock.

Altimmune Stock Up 5.9%

Shares of NASDAQ ALT opened at $5.95 on Tuesday. The stock has a market capitalization of $482.59 million, a price-to-earnings ratio of -3.84 and a beta of 0.58. The stock’s fifty day simple moving average is $5.13 and its 200 day simple moving average is $6.31. Altimmune, Inc. has a 52-week low of $3.55 and a 52-week high of $11.16.

Altimmune (NASDAQ:ALTGet Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.09. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. During the same quarter in the previous year, the company posted ($0.34) earnings per share. As a group, analysts anticipate that Altimmune, Inc. will post -1.35 earnings per share for the current year.

Wall Street Analyst Weigh In

ALT has been the subject of several research reports. William Blair reissued a “market perform” rating on shares of Altimmune in a research note on Friday, March 14th. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Altimmune in a research report on Thursday, April 3rd. Finally, Wall Street Zen upgraded Altimmune from a “sell” rating to a “hold” rating in a research note on Thursday, May 22nd. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $20.20.

Check Out Our Latest Stock Analysis on ALT

Altimmune Profile

(Free Report)

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.

Further Reading

Want to see what other hedge funds are holding ALT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Altimmune, Inc. (NASDAQ:ALTFree Report).

Institutional Ownership by Quarter for Altimmune (NASDAQ:ALT)

Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.